Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.48 |
| ▸ | SCN7A | Q01118 | 7/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.48 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851550 | 0.83 | HRH3 (0.52) | HRH3KCNH2EGLN2 | |
| SCHEMBL851451 | 0.83 | SCN9A (0.63) | KCNH2SCN7ASCN9AMKNK1MKNK2 | |
| SCHEMBL16966986 | 0.80 | SCN9A (0.78) | KCNH2SCN7ASCN9ASCN10ASCN5A | |
| SCHEMBL850540 | 0.79 | PDE4B (0.48) | HRH3SCN9APDE4BEGLN2 | |
| SCHEMBL14342678 | 0.74 | HRH3 (0.91) | HRH3KCNH2SCN7ASCN9ASCN10A | |
| SCHEMBL1375337 | 0.74 | SIGMAR1 (0.64) | KCNH2SCN7ASCN9AMKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL7718789 | 0.72 | SIGMAR1 (0.62) | KCNH2SCN7ASCN9AMKNK1MKNK2 | |
| SCHEMBL851561 | 0.72 | KDM4E (0.47) | HRH3SCN9APDE4B | |
| SCHEMBL13093862 | 0.72 | HRH3 (0.80) | HRH3KCNH2SIGMAR1 | |
| SCHEMBL851706 | 0.71 | SCN7A (0.55) | HRH3KCNH2SCN7ASCN9ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140200225-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2014-07-17 | — | — | US | disclosed |
| US-8722930-B2 | Protease inhibitors | ORION CORPORATION (FI) | 2014-05-13 | — | — | US | disclosed |
| US-20120136002-A1 | PROTEASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-31 | — | — | US | disclosed |
| EP-2432556-A1 | PROTEASE INHIBITORS | Orion Corporation (FI) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133748-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200225-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | HRH3 2164/4885KCNH2 4297/4885SCN7A 2970/4885 |
| US-20120136002-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | HRH3 2164/4885KCNH2 4297/4885SCN7A 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.